GlassScriptPhysician profile
Belinda Maples
NPI 1245223684
$6,535.35
in general payments reported to CMS, 2019-2025
42 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $1,096 · 2021: $1,562 · 2022: $1,468 · 2023: $993 · 2024: $562 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $986.72 | 2021-2024 | |
| Novo Nordisk INC | $918.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.18 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $404.22 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $394.69 | 2020-2023 | Shingrix, Bexsero, Pediarix |
| Lilly USA, LLC | $372.81 | 2019-2023 | Mounjaro |
| Pfizer INC. | $372.07 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $346.52 | 2021-2024 | |
| Daiichi Sankyo INC. | $271.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $239.68 | 2019-2025 | |
| Astellas Pharma US INC | $224.14 | 2020-2023 | Myrbetriq |
| Allergan, INC. | $187.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $134.14 | 2020-2021 | |
| Mylan Specialty L.P. | $122.88 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.60 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belinda Maples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.